Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

RIDGEFIELD, Conn., Feb. 20, 2013 /PRNewswire/ -- New findings from two double-blind, randomized trials, RE-MEDYSM and RE-SONATE®, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE)*. The results were published today in the New England Journal of Medicine.

VTE is the third most common cardiovascular disorder after heart disease and stroke, and consists of two related conditions caused by blood clots: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is when a blood clot develops in the deep veins of the leg or pelvis. The clot, or part of it, can break off from the site where it formed and travel through the veins (embolism). A PE can occur if the clot lodges in the arteries of the lungs.

There are an estimated 900,000 VTE events per year in the U.S., approximately one-third of which result in death from PE. Further, roughly one-third of people with VTE will have a recurrence within 10 years. The standard of care for patients with VTE is anticoagulation.

RE-MEDY demonstrated that treatment with dabigatran 150 mg twice daily was non-inferior to warfarin (p=0.01) in preventing recurrent VTE, including VTE-related death. RE-SONATE demonstrated dabigatran was superior to placebo for the prevention of first recurrent or fatal VTE with a risk reduction of 92 percent during the treatment period (p<0.001). Lower event rates were reported across all secondary efficacy endpoints for dabigatran over placebo.

"Patients who suffer one VTE event are at increased risk of suffering another, with the risk accumulating over time," said Sam Schulman , M.D., Ph.D., FRCPC(C), lead study author and professor, Department of Medicine, McMaster University, Ontario, Canada. "We are encouraged to see that the RE-MEDY and RE-SONATE trials met their endpoints and we will continue to study the safety, efficacy and p
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... 2015  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... Hata to its board of directors. ... development is a tremendous asset to our board," said ... officer of Xencor. "Xencor faces a range of opportunities ...
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Calif., Oct. 27 ... beamforming technology, analog-front-end semiconductors and solutions for the ... Ultrasound Beamforming Development Kit.  Based on Samplify,s AutoFocus™ ... solution for the ultrasound front end, from probe ...
... Oct. 27 Solos Endoscopy, Inc. (Pink Sheets: ... revenues during the three months ended September 30, 2010 in ... ended September 30, 2009.  This was an increase of 34.8% for ... Despite a down global economy, Solos has been able ...
Cached Medicine Technology:Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 2Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 3Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010 2
(Date:7/31/2015)... ... ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in Seattle, ... it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising ... will grant 100% of the money raised to BioViva to help bring pioneering gene ...
(Date:7/31/2015)... Church, VA (PRWEB) , ... July 31, 2015 ... ... Way, Oct. 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated ... it doesn’t have to. , Instead of risking containment — or even destruction ...
(Date:7/31/2015)... Tampa, FL (PRWEB) , ... July 31, 2015 ... ... cancer patients using the RenovoCath,™ a novel catheter that was developed for targeted ... locally-advanced pancreatic cancer are now being treated at Florida Hospital Tampa with the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National Team ... September 17th at Ford Field in Detroit and the second match will occur in ...
(Date:7/31/2015)... ... ... Indosoft, Inc., is pleased to announce a major update to its agent interface ... ACD system for Asterisk-based call centers . The new features make it easier ... agent only when wanted, and allows for validation of data as the agent enters ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... Accepts as Complete DNV,s ... Hospital Deeming Authority, HOUSTON, March 24 The U.S. ... that its application to,deem hospitals in compliance with the Medicare ... formal review., If approved, DNV stands to become the ...
... Control of all Sites from a Single ... ... Dayton,Ohio has chosen multiple products from Sage Software - including the,Intergy by ... and improve the,patient experience. Previously, Digestive Specialists used The Medical,Manager by Sage., ...
... March 24 MedCath Corporation,(MedCath) (Nasdaq: MDTH ... Ohio) jointly announced today that the parties have,entered ... Samaritan,Hospital will acquire substantially all of Dayton Heart ... $55.0 million, a portion of,which is allocated to ...
... they,re not getting needed screenings for breast and cervical tumors ... of 32 studies suggests that obese women -- particularly white ... for breast and cervical cancer. , No one knows ... mammograms or Pap smears. And it,s not known why obesity ...
... BOSTON, March 24 "Going head-to-head with your child,can be ... ask,for some extra reading at bedtime and, before you know ... that you can,t refuse.,Well, if I can,t stay up late ... I guess you owe me a back rub and two ...
... Joint ST/Veredus lab set up in Singapore to develop future lab-on-chip ... ... SINGAPORE, March 24 Following the,success of the evaluation trials conducted ... STM ) today announced the commercial availability,of VereFlu(TM), a portable ...
Cached Medicine News:Health News:DNV Healthcare Advances in Bid to Accredit Hospitals 2Health News:Multi-site Gastro Practice Chooses Intergy by Sage Practice Management System 2Health News:MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton 2Health News:MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton 3Health News:Obese Women Less Likely to Be Tested for Some Cancers 2Health News:HOW TO UNSPOIL YOUR CHILD FAST: Harvard Medical School Psychologist Writes Book to Guide and Motivate Parents and Support the Children's Defense Fund 2Health News:STMicroelectronics and Veredus Laboratories Launch Market's First Lab-on-Chip for Rapid Molecular Flu Detection at Point of Need 2Health News:STMicroelectronics and Veredus Laboratories Launch Market's First Lab-on-Chip for Rapid Molecular Flu Detection at Point of Need 3
Illuminated Phoroptor Refracting Instrument. Illumination is provided by a cool-running, energy efficient LEDs (Light Emitting Diodes) that light only what you need to see without affecting the darke...
Red Lens Maddox...
The Snellen chart is the default optotype with the standard order of letters (T Z V E C L) as default. When the Refresh 'R' button is pressed, the letters ( or pictures ) are replaced with a random s...
Snellen 20' Eye Test Chart....
Medicine Products: